Novo Nordisk A/S
NVO
62.63
USD+1.33
(+2.17%)Day's range
61.8419
62.74
52 wk Range
57
148.15
Key ratios
Statements Highlights
| Period Ending | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
|---|---|---|---|---|---|---|
| Total Revenue | 126,946,000,000 | 140,800,000,000 | 176,954,000,000 | 232,261,000,000 | 290,403,000,000 | |
| Gross Profit | 106,014,000,000 | 117,142,000,000 | 148,506,000,000 | 196,496,000,000 | 245,881,000,000 | |
| Operating Income | 54,126,000,000 | 58,644,000,000 | 74,809,000,000 | 102,574,000,000 | 128,339,000,000 | |
| Net Income | 42,138,000,000 | 47,757,000,000 | 55,525,000,000 | 83,683,000,000 | 100,988,000,000 | |
| Total Assets | 144,922,000,000 | 194,508,000,000 | 241,257,000,000 | 314,486,000,000 | 465,795,000,000 | |
| Total Current Liabilities | 70,273,000,000 | 99,516,000,000 | 120,940,000,000 | 169,655,000,000 | 217,528,000,000 | |
| Total Equity | 63,325,000,000 | 70,746,000,000 | 83,486,000,000 | 106,561,000,000 | 143,486,000,000 | |
| Free Cash Flow | 29,870,000,000 | 47,615,000,000 | 64,134,000,000 | 70,012,000,000 | 69,659,000,000 | |
| Cash from Operations | 51,951,000,000 | 55,000,000,000 | 78,887,000,000 | 108,908,000,000 | 120,968,000,000 | |
| Cash from Investing | -22,436,000,000 | -31,605,000,000 | -24,918,000,000 | -43,892,000,000 | -128,895,000,000 | |
| Cash from Financing | -32,244,000,000 | -25,493,000,000 | -51,797,000,000 | -63,158,000,000 | 8,735,000,000 | |
| Net Change in Cash | -3,185,000,000 | -1,507,000,000 | 1,934,000,000 | 1,739,000,000 | 1,263,000,000 |
Dividends
Analyst Recomendations
Overall consensus
Buy